Aurobindo Pharma shares gain on U.S. FDA’s VAI classification of oral solid dosage unit

Generic drugmaker Aurobindo Pharma shares touched a new 52-week high on Wednesday (May 6, 2026) on the back of U.S. Food and Drug Administration (U.S. FDA) classifying a key manufacturing plant, it had inspected recently, as voluntary action indicated (VAI).

The unit has now received Establishment Inspection Report (EIR) classifying the facility as VAI. The U.S. FDA has concluded that the inspection is now closed, Aurobindo said in an intimation to the stock exchange about its oral solid dosage manufacturing unit near Hyderabad.

The U.S. FDA had inspected the company’s facility (Unit-VII) from January 28 to February 10. At the end of the inspection, it has issued a Form 483 with a total of nine observations.

One of the three classifications, the U.S. FDA issues for its inspections, voluntary action indicated or VAI means objectionable conditions or practices were found, but the regulator is not prepared to take or recommend any administrative or regulatory action.

OAI is another classification and severest categorising and means regulatory and/or administrative actions are recommended.

No action indicated (NAI) is the third classification conveying that no objectionable conditions or practices were found during inspection.

Aurobindo Pharma shares closed 3.87% higher on the BSE at ₹1,483.40 each. Intra day the shares touched a new 52-week high of ₹1,489.10 each.